Avail Scientific

08/03/2022

Amazing new podcast with Adam Tapp and Ken Kirkwood, Associate Professor at Western University in the fields of Bioethics, discussing the modern history of psychedelic and drug use

‎Show Tapped Into Psychedelics, Ep Modern History of Psychedelics Use with Ken Kirkwood - Aug 1, 2022

08/03/2022

‘This is the landmark case that is going to legalize psychedelics in Canada’

The plaintiffs argue that current modes of accessing psilocybin are a violation of Section 7 of the Canadian Charter of Rights and Freedoms

07/28/2022

Dr. Ishrat Husain - "Clinical trials suggest , combined with intensive , can produce sustained antidepressant effects in those living with severe ."

Toronto's Centre for Addiction and Mental Health (CAMH) says it has received the first-ever federal grant to study whether the active component in 'magic' mushrooms can be used to treat depression without the psychedelic effects.

07/25/2022

Research proving what many thought obvious.

Psilocybin, the active compound in “magic mushrooms,” has been shown to be a promising treatment for various mental health issues. New research published in Scientific Reports found that people who microdose psychedelics displayed greater improvements in mental health and mood over the span of 1...

07/21/2022

treatments are working - now it's time to make it legal

Here’s how the psychedelic substance’s legal status has been shifting

07/19/2022

One of the best primers on the new revolution. Streaming now on

Author Michael Pollan leads the way in this docuseries exploring the history and uses of psychedelics, including L*D, psilocybin, M**A and mescaline.

07/15/2022

Scientists at UC San Francisco and Imperial College London found that psilocybin fosters greater connections between different regions of the brain in depressed people, freeing them up from long-held patterns of rumination and excessive self-focus.

07/12/2022

A bill is now before a Pa. House committee, but its prospects appear uncertain.

07/10/2022

Professor David Hellerstein is a Professor of Clinical Psychiatry at Columbia University, New York. He talks about the positive results of of their phase IIb trial of psilocybin therapy for treatment-resistant depression.

Professor David Hellerstein is a Professor of Clinical Psychiatry and Principal Investigator on COMPASS Pathways’ trial site at Columbia University, New York...

06/28/2022

Adam Tapp, Senior VP of Product Development at Avail Scientific, conducts a fantastic interview with Tyler Watson of White Crest Mushrooms.

‎Show Tapped Into Psychedelics, Ep Fantastical Fungi with Mycologist Tyler Watson - Jun 1, 2022

05/27/2022

Biggest study of its kind to date shows that is a powerful therapeutic for treating depression

After 12 months, 70% of the participants still had antidepressant responses while over half were in remission. “Psilocybin not only produces significant...

05/19/2022

In what is absolutely a sign that the new interest in psychedelic drugs has landed, a new commercial facility has opened for trials in London, UK.

The first commercial facility in Europe designed to trial psychedelic drugs opens its doors in the U.K.